Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
325
datasets available to search
ShareScore release 0.9.0
Dataset results
325 results for “circulating tumor cells”
COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT01596790. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cultured Circulating Tumor Cells in Prostate and Other Cancers
ClinicalTrials.gov study NCT02123862. IPD Sharing: Not stated. Countries: 1. Publications: 9.
Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells
ClinicalTrials.gov study NCT01286883. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Influence of Opioids on Circulating Tumor Cells in Radical Cystectomy
ClinicalTrials.gov study NCT04358718. IPD Sharing: NO. Countries: 1. Publications: 1.
The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
ClinicalTrials.gov study NCT02450448. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Generation of a monoclonal antibody recognizing the heavily glycosylated CD45 Protein and its application on identifying circulating tumor cells
Here, we provide direct evidence that using recombinant proteins expressed in eukaryotic cells as antigen is a practical way to generate monoclonal antibodies (mAbs) against heavily glycosylated proteins. Heavily glycosylated proteins are typically difficult targets for mAb generation, being limited by unsatisfactory affinity and low specificity. Using the heavily glycosylated CD45 protein as an example, we demonstrate the entire process of expressing the protein in eukaryotic cells and using it as an antigen to generate CD45-targeting mAbs in mice. The mAbs generated showed robust affinity and specificity, which are crucial factors for differentiate circulating tumor cells from white blood cells in human breast cancer patient samples. Only 1 cell fusion and 2 cyclic sub-cloning steps were necessary before mAbs with satisfactory performance were obtained.
Data from: High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1
Background: Expression of programmed-death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) is typically evaluated through invasive biopsies; however, recent advances in the identification of circulating tumor cells (CTCs) may be a less invasive method to assay tumor cells for these purposes. These liquid biopsies rely on accurate identification of CTCs from the diverse populations in the blood, where some tumor cells share characteristics with normal blood cells. While many blood cells can be excluded by their high expression of CD45, neutrophils and other immature myeloid subsets have low to absent expression of CD45 and also express PD-L1. Furthermore, cytokeratin is typically used to identify CTCs, but neutrophils may stain non-specifically for intracellular antibodies, including cytokeratin, thus preventing accurate evaluation of PD-L1 expression on tumor cells. This holds even greater significance when evaluating PD-L1 in epithelial cell adhesion molecule (EpCAM) positive and EpCAM negative CTCs (as in epithelial-mesenchymal transition (EMT)). Methods: To evaluate the impact of CTC misidentification on PD-L1 evaluation, we utilized CD11b to identify myeloid cells. CTCs were isolated from patients with metastatic NSCLC using EpCAM, MUC1 or Vimentin capture antibodies and exclusion-based sample preparation (ESP) technology. Results: Large populations of CD11b+CD45lo cells were identified in buffy coats and stained non-specifically for intracellular antibodies including cytokeratin. The amount of CD11b+ cells misidentified as CTCs varied among patients; accounting for 33–100% of traditionally identified CTCs. Cells captured with vimentin had a higher frequency of CD11b+ cells at 41%, compared to 20% and 18% with MUC1 or EpCAM, respectively. Cells misidentified as CTCs ultimately skewed PD-L1 expression to varying degrees across patient samples. Conclusions: Interfering myeloid populations can be differentiated from true CTCs with additional staining criteria, thus improving the specificity of CTC identification and the accuracy of biomarker evaluation.
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
ClinicalTrials.gov study NCT01701050. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Anderson Circulating Tumor Cell Burden (CTCB) Study
ClinicalTrials.gov study NCT00819832. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
ClinicalTrials.gov study NCT06736613. IPD Sharing: YES. Countries: 1. Publications: 0.
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
ClinicalTrials.gov study NCT03070002. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
ClinicalTrials.gov study NCT00887640. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT03213041. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
ClinicalTrials.gov study NCT04229121. IPD Sharing: NO. Countries: 0. Publications: 3.
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
ClinicalTrials.gov study NCT06914011. IPD Sharing: NO. Countries: 0. Publications: 4.
Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device
ClinicalTrials.gov study NCT04239105. IPD Sharing: NO. Countries: 0. Publications: 37.
Measurement of Circulating Tumor Cells in Prostate Cancer
ClinicalTrials.gov study NCT04101305. IPD Sharing: NO. Countries: 1. Publications: 0.
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
ClinicalTrials.gov study NCT00429182. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Data from: Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing
Open the record for dataset details and reuse information.
Data from: Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.